Market closed

Cytosorbents/$CTSO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Cytosorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Ticker

$CTSO
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Equipment & Supplies
Headquarters
Princeton, United States

Employees

186
Website
www.cytosorbents.com

Cytosorbents Metrics

BasicAdvanced
$57M
-
-$0.36
0.56
-

$57M

0.56

$1.50

$0.70

415K

1.969

1.461

202.897

206.22

-25.19%

-27.30%

-118.50%

1.458

4.4

4.4

-2.869

1.80%

-33.22%

-5.23%

-1.06%

What the Analysts think about Cytosorbents

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cytosorbents stock.

Cytosorbents Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cytosorbents Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Cytosorbents News

AllArticlesVideos
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

GlobeNewsWire·2 weeks ago
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

GlobeNewsWire·1 month ago
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CTSO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cytosorbents stock?

Cytosorbents (CTSO) has a market cap of $57M as of January 15, 2025.

What is the P/E ratio for Cytosorbents stock?

The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of January 15, 2025.

Does Cytosorbents stock pay dividends?

No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Cytosorbents dividend payment date?

Cytosorbents (CTSO) stock does not pay dividends to its shareholders.

What is the beta indicator for Cytosorbents?

Cytosorbents (CTSO) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.